The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Rheumatoid Arthritis (RA) Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
The global Rheumatoid Arthritis (RA) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rheumatoid Arthritis (RA) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Rheumatoid Arthritis (RA) Drugs market. NSAIDs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Analgesic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rheumatoid Arthritis (RA) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rheumatoid Arthritis (RA) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rheumatoid Arthritis (RA) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rheumatoid Arthritis (RA) Drugs covered in this report include AbbVie, Roche, Merck, HEYL Chemisch-pharmazeutische Fabrik, Johnson & Johnson, Amgen, Inc., Pfizer, Bristol-Myers Squibb and UCB, etc.
The global Rheumatoid Arthritis (RA) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Global Rheumatoid Arthritis (RA) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rheumatoid Arthritis (RA) Drugs market, Segment by Type:
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Global Rheumatoid Arthritis (RA) Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
The global Rheumatoid Arthritis (RA) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Rheumatoid Arthritis (RA) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Rheumatoid Arthritis (RA) Drugs market. NSAIDs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Analgesic Drugs segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rheumatoid Arthritis (RA) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rheumatoid Arthritis (RA) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rheumatoid Arthritis (RA) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rheumatoid Arthritis (RA) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rheumatoid Arthritis (RA) Drugs covered in this report include AbbVie, Roche, Merck, HEYL Chemisch-pharmazeutische Fabrik, Johnson & Johnson, Amgen, Inc., Pfizer, Bristol-Myers Squibb and UCB, etc.
The global Rheumatoid Arthritis (RA) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Global Rheumatoid Arthritis (RA) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rheumatoid Arthritis (RA) Drugs market, Segment by Type:
NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors
Global Rheumatoid Arthritis (RA) Drugs market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Rheumatoid Arthritis (RA) Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Rheumatoid Arthritis (RA) Drugs
1.1 Rheumatoid Arthritis (RA) Drugs Market Overview
1.1.1 Rheumatoid Arthritis (RA) Drugs Product Scope
1.1.2 Rheumatoid Arthritis (RA) Drugs Market Status and Outlook
1.2 Global Rheumatoid Arthritis (RA) Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Rheumatoid Arthritis (RA) Drugs Market Size by Region (2018-2029)
1.4 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Region (2018-2023)
1.5 Global Rheumatoid Arthritis (RA) Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
1.6.1 North America Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
1.6.2 Europe Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
1.6.4 Latin America Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size (2018-2029)
2 Rheumatoid Arthritis (RA) Drugs Market by Type
2.1 Introduction
2.1.1 NSAIDs
2.1.2 Analgesic Drugs
2.1.3 Corticosteroids
2.1.4 DMARDs
2.1.5 Biological Therapies
2.1.6 JAK-inhibitors
2.2 Global Rheumatoid Arthritis (RA) Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Type (2018-2029)
3 Rheumatoid Arthritis (RA) Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Rheumatoid Arthritis (RA) Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Rheumatoid Arthritis (RA) Drugs Revenue Breakdown by Application (2018-2029)
4 Rheumatoid Arthritis (RA) Drugs Competition Analysis by Players
4.1 Global Rheumatoid Arthritis (RA) Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rheumatoid Arthritis (RA) Drugs as of 2022)
4.3 Date of Key Players Enter into Rheumatoid Arthritis (RA) Drugs Market
4.4 Global Top Players Rheumatoid Arthritis (RA) Drugs Headquarters and Area Served
4.5 Key Players Rheumatoid Arthritis (RA) Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Rheumatoid Arthritis (RA) Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 AbbVie
5.1.1 AbbVie Profile
5.1.2 AbbVie Main Business
5.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.1.4 AbbVie Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 AbbVie Recent Developments
5.2 Roche
5.2.1 Roche Profile
5.2.2 Roche Main Business
5.2.3 Roche Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.2.4 Roche Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Roche Recent Developments
5.3 Merck
5.3.1 Merck Profile
5.3.2 Merck Main Business
5.3.3 Merck Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.3.4 Merck Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 HEYL Chemisch-pharmazeutische Fabrik Recent Developments
5.4 HEYL Chemisch-pharmazeutische Fabrik
5.4.1 HEYL Chemisch-pharmazeutische Fabrik Profile
5.4.2 HEYL Chemisch-pharmazeutische Fabrik Main Business
5.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.4.4 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.5.4 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
5.6 Amgen, Inc.
5.6.1 Amgen, Inc. Profile
5.6.2 Amgen, Inc. Main Business
5.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.6.4 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Amgen, Inc. Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.7.4 Pfizer Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Bristol-Myers Squibb
5.8.1 Bristol-Myers Squibb Profile
5.8.2 Bristol-Myers Squibb Main Business
5.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.8.4 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Bristol-Myers Squibb Recent Developments
5.9 UCB
5.9.1 UCB Profile
5.9.2 UCB Main Business
5.9.3 UCB Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.9.4 UCB Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 UCB Recent Developments
5.10 GSK
5.10.1 GSK Profile
5.10.2 GSK Main Business
5.10.3 GSK Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.10.4 GSK Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 GSK Recent Developments
5.11 Sanofi
5.11.1 Sanofi Profile
5.11.2 Sanofi Main Business
5.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.11.4 Sanofi Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Sanofi Recent Developments
5.12 Abbott Laboratories
5.12.1 Abbott Laboratories Profile
5.12.2 Abbott Laboratories Main Business
5.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.12.4 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Abbott Laboratories Recent Developments
5.13 Teva Pharmaceutical
5.13.1 Teva Pharmaceutical Profile
5.13.2 Teva Pharmaceutical Main Business
5.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Products, Services and Solutions
5.13.4 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 Teva Pharmaceutical Recent Developments
6 North America
6.1 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Rheumatoid Arthritis (RA) Drugs Market Dynamics
11.1 Rheumatoid Arthritis (RA) Drugs Industry Trends
11.2 Rheumatoid Arthritis (RA) Drugs Market Drivers
11.3 Rheumatoid Arthritis (RA) Drugs Market Challenges
11.4 Rheumatoid Arthritis (RA) Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
